Johnson & Johnson (JNJ) Sell-Side Expectations

Sell Side Expectations High Mean Low Sales (in millions) $74,806 $73,900 $72,590 EPS $6.02 $5.85 $5.75 Price Target $105.00 $97.32 $86.00 Credit Suisse Stance / Rating Underperform $86 $5.39 Credit Suisse says positive progress is in motion in all three J&J divisions. UBS Buy $89 $5.41 UBS believes Barclays Overweight $99 $5.45 Goldman Sachs Barclays has adjusted Goldman Sachs Neutral $95 $5.40 Target Price EPS 2013E that the Pharma says a case and Consumer can be made for J&J to spin its revenue outlook for out its Pharma FY13 modestly J&J a positively business as an for foreign independently- exchange fluctuations. The company believes EPS segments should give Pharma product differentiated launches last year helped mitigate patent US large-cap cliff issues and peers over the will drive above- intermediate average growth term, and through 2015. The acquisition tougher of Synthes is accretive, and offers both an offensive and defensive mix margin outlook traded vs. many other biopharma company. It notes that the Pharma will be at the high end of guidance at $5.45. Barclays has also raised its pipeline is on track to deliver despite a situation in the MD&D segment. 10 new drugs by 2017 on an approximate budget of $8 billion (2013E). segment sales FY 13 estimates for Pharma from $26.2 billion to $27.2 billion. for MD&D. SOURCES: Sell Side Estimates, Bloomberg Professional Services BIDNESS etc. DISCLAIMER: Bidness Etc(TM) and related marks are owned by Bidness Etc. Any other trademarks appearing on this website are the property of their respective owners, and are not used to indicate the origin of goods or services offered or provided by Bidness Etc herein or to suggest approval for or affiliation with Bidness Etc.